Methodological Consensus Diseases Consensus State of the Art of Related Disciplines
Methodological Consensus
> Introduction
> Expert Clinical Group
> Objectives
> Methodology
> Workflow
> Evidence Based Methodology
> Consensus statement
> General instructions
> Conflicting points
> Voting Results

Conflicting Points

1. Eligibility
V. Verwaal

Curriculum Vitae
2. Pre-operative work-up
T.D. Yan

Curriculum Vitae
3.Intraoperative staging system
A. Gomez Portilla

Curriculum Vitae
4.Technical aspects of the cytoreductive surgery
S. O’Dwyer

Curriculum Vitae
5.Residual disease evaluation
S. Moreno Gonzalez

Curriculum Vitae
6A. Hyperthermic Intraoperative Chemotherapy: nomenclature and modality of perfusion
O. Glehen

Curriculum Vitae
6B. Chemotherapies, carrier solution and optimal temperature
D. Elias

Curriculum Vitae
7.Morbidity, toxicity and mortality classification systems
R. Younan

Curriculum Vitae
News
Submit your abstract >
Registration and Accommodation >

2. Preoperative Workup

2.1. In the preoperative workup of a patient candidate to cytoreductive surgery and heated intraperitoneal chemotherapy please classify the following alternatives according to the level of importance/priorit. (just one alternative allowed)

Exam a b c
1. Thin slice CT scan (with adequate intravenous, oral, +/- rectal contrast media) [5],[6],[7] 96,77 %
100,00 %
3,23 %
0 %
0 %
0 %
2. PET total body[8],[9] 19,35 %
6,25 %
64,52 %
84,38 %
16,13 %
9,38 %
3. Magnetic resonance imaging [10]
,
[11],[12],[13]
12,90 %
3,13 %
70,97 %
81,25 %
16,13 %
15,63 %
4. Abdominal laparoscopy [14],[15] 16,13 %
9,38 %
70,97 %
78,13 %
12,90 %
12,50 %
5.Serum tumour markers (ca125,
CEA, Ca19.9)
[16],[17],[18]
32,26 %
21,88 %
54,84 %
71,88 %
12,90 %
6,25 %

a: fundamental; b: useful but not fundamental; c: useless.

References

5] de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004 May 1;86(2):64-73. Review.
[6] de Bree E, Koops W, Kroger R, van Ruth S, Verwaal VJ, Zoetmulder FA. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2006 Feb;32(1):65-71. Epub 2005 Nov 14
[7] Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.Cancer. 2005 Feb 15;103(4):839-49.
[8] Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003 Sep;44(9):1407-12.
[9] Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005 Jun 1;103(11):2383-90.
[10] Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology. 1997 Aug;204(2):513-20.
[11] Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, Haller U, Steinert HC. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10(5):761-7.
[12] Ricke J, Hosten N. Peritoneal carcinomatosis. Abdom Imaging. 1997 Mar-Apr;22(2):235-6.
[13] Chou CK, Liu GC, Chen LT, Jaw TS. MRI manifestations of peritoneal carcinomatosis. Gastrointest Radiol. 1992 Fall;17(4):336-8.
[14] Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005 Jun;31(5):540-3.
[15] Garofalo A, Valle M. [Staging videolaparoscopy of peritoneal carcinomatosis] Tumori. 2003 Jul-Aug;89(4 Suppl):70-7. Review. Italian.
[16]. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva GD, Deraco M. Role of circulating tumor markers in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006 In press.
[17].Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis. 2005 Jul;7(4):382-6.
[18] Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva GD, Deraco M. Prognostic value of serum tumor marker determination in patients affected by pseudomyxoma peritonei treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006 In press

-----------------------------------------------------------------------------------------------

home | back | mail | top | credits